BMO Capital reiterated an Outperform rating and $36 price target on Pfizer (PFE), saying that 2025 guidance succeeds in meeting the majority of the firm’s expectations outlined in its preview, positioning the company for earnings per share expansion. The company’s guide only just missed the firm’s midpoint sales expectation, though midpoint EPS expectations of $2.90 in 2025 show roughly 2% growth year-over-year, giving investors confidence that the company has turned over a new leaf financially, the analyst tells investors in a research note. The firm continues to believe the revenue guidance is conservative, especially for ex-COVID products, leaving room for future beats and raises to sustain shares throughout the year.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PFE:
- Barclays fact-checked Trump comments on pharmacy benefit managers
- Pfizer provides FY25 outlook, McCormick in talks for Sauer Brands: Morning Buzz
- Pfizer (NYSE:PFE) Surges as FY25 Forecast Aligns with Wall Street
- Early notable gainers among liquid option names on December 17th
- Morning Movers: Rockwell Medical jumps following product purchase agreement
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
